Abstract | BACKGROUND: METHODS: To investigate the efficacy of EC-18 on the development of RA, EC-18 was administered in a collagen-induced arthritis (CIA) murine model and disease severity and the level of inflammatory cytokines in the joint were investigated. The effect of EC-18 on the inflammation-related factors was investigated by flow cytometry, ELISA, western blot, and real-time PCR in splenocytes from mice and in peripheral blood mononuclear cells from healthy and patients with RA. The effect of EC-18 on osteoclastogenesis was investigated. RESULTS: EC-18 effectively reduced the clinical and histological severity of arthritis, similar to Janus kinase inhibitors include tofacitinib and baricitinib, in CIA. Furthermore, EC-18 exhibited a synergistic effect with methotrexate in preventing CIA. Treatment with EC-18 effectively reduced the production of inflammatory cytokines in immune cells and osteoclast differentiation in mice and patients with RA. CONCLUSION: These results suggest that EC-18 may be an effective strategy for RA.
|
Authors | Jin-Sil Park, Seung Cheon Yang, Ha Yeon Jeong, Seon-Young Lee, Jun-Geol Ryu, Jeong Won Choi, Hye Yeon Kang, Sung-Min Kim, Sun-Hee Hwang, Mi-La Cho, Sung-Hwan Park |
Journal | Arthritis research & therapy
(Arthritis Res Ther)
Vol. 24
Issue 1
Pg. 254
(11 17 2022)
ISSN: 1478-6362 [Electronic] England |
PMID | 36397156
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2022. The Author(s). |
Chemical References |
|
Topics |
- Mice
- Animals
- Osteogenesis
- Cytokines
(pharmacology)
- Leukocytes, Mononuclear
(pathology)
- Arthritis, Experimental
- Arthritis, Rheumatoid
(drug therapy)
|